These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11585445)

  • 1. Synthesis of potent C(2)-symmetric, diol-based hiv-1 protease inhibitors. Investigation of thioalkyl and thioaryl P1/P1' substituents.
    Mühlman A; Classon B; Hallberg A; Samuelsson B
    J Med Chem; 2001 Oct; 44(21):3402-6. PubMed ID: 11585445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal.
    Mühlman A; Lindberg J; Classon B; Unge T; Hallberg A; Samuelsson B
    J Med Chem; 2001 Oct; 44(21):3407-16. PubMed ID: 11585446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A symmetric inhibitor binds HIV-1 protease asymmetrically.
    Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
    Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.
    Pyring D; Lindberg J; Rosenquist A ; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Unge T; Classon B; Hallberg A; Samuelsson B
    J Med Chem; 2001 Sep; 44(19):3083-91. PubMed ID: 11543677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol.
    De Rosa M; Unge J; Motwani HV; Rosenquist Å; Vrang L; Wallberg H; Larhed M
    J Med Chem; 2014 Aug; 57(15):6444-57. PubMed ID: 25054811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A quantitative structure-activity relationship study on some sulfolanes and arylthiomethanes acting as HIV-1 protease inhibitors.
    Gupta SP; Babu MS; Sowmya S
    Bioorg Med Chem; 1998 Nov; 6(11):2185-92. PubMed ID: 9881109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synthesis and evaluation of cyclic ureas as HIV protease inhibitors: modifications of the P1/P1' residues.
    Patel M; Bacheler LT; Rayner MM; Cordova BC; Klabe RM; Erickson-Viitanen S; Seitz SP
    Bioorg Med Chem Lett; 1998 Apr; 8(7):823-8. PubMed ID: 9871548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The synthesis of symmetrical and unsymmetrical P1/P1' cyclic ureas as HIV protease inhibitors.
    Patel M; Kaltenbach RF; Nugiel DA; McHugh RJ; Jadhav PK; Bacheler LT; Cordova BC; Klabe RM; Erickson-Viitanen S; Garber S; Reid C; Seitz SP
    Bioorg Med Chem Lett; 1998 May; 8(9):1077-82. PubMed ID: 9871711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation and structure-activity relationship of novel P1/P1'-substituted cyclic urea-based human immunodeficiency virus type-1 protease inhibitors.
    Nugiel DA; Jacobs K; Kaltenbach RF; Worley T; Patel M; Meyer DT; Jadhav PK; De Lucca GV; Smyser TE; Klabe RM; Bacheler LT; Rayner MM; Seitz SP
    J Med Chem; 1996 May; 39(11):2156-69. PubMed ID: 8667359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased antiviral activity of cyclic urea HIV protease inhibitors by modifying the P1/P1' substituents.
    Kaltenbach RF; Klabe RM; Cordova BC; Seitz SP
    Bioorg Med Chem Lett; 1999 Aug; 9(15):2259-62. PubMed ID: 10465557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of cyclic sulfolanes as novel and high-affinity P2 ligands for HIV-1 protease inhibitors.
    Ghosh AK; Lee HY; Thompson WJ; Culberson C; Holloway MK; McKee SP; Munson PM; Duong TT; Smith AM; Darke PL
    J Med Chem; 1994 Apr; 37(8):1177-88. PubMed ID: 8164260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and fast synthesis of C-terminal duplicated potent C(2)-symmetric P1/P1'-modified HIV-1 protease inhibitors.
    Alterman M; Andersson HO; Garg N; Ahlsén G; Lövgren S; Classon B; Danielson UH; Kvarnström I; Vrang L; Unge T; Samuelsson B; Hallberg A
    J Med Chem; 1999 Sep; 42(19):3835-44. PubMed ID: 10508432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
    Wannberg J; Sabnis YA; Vrang L; Samuelsson B; Karlén A; Hallberg A; Larhed M
    Bioorg Med Chem; 2006 Aug; 14(15):5303-15. PubMed ID: 16621572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
    Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P1' oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1.
    Kim RM; Rouse EA; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4651-4. PubMed ID: 15324882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1' ligands.
    Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y
    Future Med Chem; 2020 May; 12(9):775-794. PubMed ID: 32125179
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.